Alan Shaw, Ph.D.
President and CEO
Alan Shaw, Ph.D., is President and Chief Executive Officer of Calysta, and a member of the Board of Directors. He joined in 2012. Dr. Shaw is a veteran biotechnology entrepreneur and chemical industry executive, with more than 25 years experience building and leading technology companies. Before joining Calysta, he served for ten years as President & CEO and a director of Codexis, a developer of cost-advantaged processes for production of biobased chemicals and pharmaceuticals. During his tenure, Codexis completed an IPO and expanded from a startup to a global industrial biotechnology company with operations in the United States, Europe and Asia.
In 2010, Dr. Shaw received the Ernst and Young Entrepreneur® of the Year Award in the life sciences category for Northern California. He is a member of the Board of Directors of BIO and the Governing Board of the BIO Industrial and Environmental Section. He also serves as a biotechnology advisor to the governments of the United Kingdom and Malaysia, and is a frequent speaker at leading business and industry conferences.
Prior to Codexis, Dr. Shaw held senior operating and business development positions in the United Kingdom for Chiroscience Group plc and for the chemical and biopharmaceutical units of Clariant and BTP plc from 1994-99. For the previous 15 years, he held management and scientific leadership positions for Imperial Chemical Industries plc (ICI)/Zeneca, including Business Head, Fine Chemicals and Marketing Manager, European Sales. He holds a bachelor’s degree in chemistry from Teesside University and a Ph.D. in chemistry from the University of Durham, England. He is a Fellow of the Royal Society of Chemistry and a Fellow of the Chartered Institute of Marketing.
Vice President, Global Capital Projects
Graham Aylen, CEng.,is Vice President for Global Capital Projects at Calysta, and Managing Director of Calysta UK Limited. Mr. Aylen joined Calysta in 2014, working on the acquisition of Calysta AS in Norway. He currently focuses on the delivery of the small scale facility project in the United Kingdom and the commercialization of FeedKind™ protein.
Prior to joining Calysta, he held positions where he was responsible for the safe delivery of large scale capital projects in the fine chemical, pharmaceutical and biotechnology industries internationally with ICI, Zeneca, Avecia, Costain, GSK, Pfizer, Anglian Water and Codexis.
Mr. Aylen has also worked on professional committees developing policy with the UK and Malaysian Government and the IChemE.
Tomas Belloso, Ph.D.
Vice President, Regulatory Affairs
Tomas Belloso, Ph.D., joined Calysta as Vice President, Regulatory Affairs in 2016. He reports to Josh Silverman, Ph.D., Chief Product and Innovation Officer, and is responsible for the company’s regulatory and quality management programs and strategy.
Dr. Belloso has over a decade of senior regulatory, quality and product management experience in the feed and animal health industries. Before joining Calysta, he served as Regulatory Compliance Manager at the Feed Division of Wilbur-Ellis, a $3 billion international marketer and distributor of agricultural products, animal feed and specialty chemicals and ingredients. Prior to that, he held senior regulatory and product management positions at Royal Canin USA, a subsidiary of MARS, Inc., Nestle Purina, Monsanto and Elanco Animal Health.
He holds a Ph.D. in animal sciences and a Master’s degree in dairy sciences from the University of Florida, and a Bachelor’s degree in animal sciences from Universidad Rafael Urdaneta in Venezuela.
Blake Campbell joined Calysta in 2016 as the company’s General Counsel. He has responsibility for the company’s global legal strategy, planning and management. Prior to Calysta, Mr. Campbell served as General Counsel for Extend Health, Inc. and AlphaImpactRx, Inc. and as a senior attorney for several global law firms. Mr. Campbell has also served as a senior adviser to former California Senator and Governor Pete Wilson in Washington D.C. and Sacramento.
Mr. Campbell specializes in general corporate and finance matters and has extensive experience with project finance transactions, strategic and cross-border transactions, technology transfers, joint development and strategic IP licensing and portfolio management, mergers and acquisitions, initial public offerings, venture financings, executive compensation, board and committee support and governance, SEC/SOX/NASDAQ compliance and reporting and risk and litigation management.
Mr. Campbell holds a Bachelor of Arts from Stanford University and a JD from the University of California at Los Angeles.
Lori Giver, Ph.D.
Vice President, Biological Engineering
Lori Giver, Ph.D. is the Vice President of Biological Engineering at Calysta. She joined Calysta in 2013 and is responsible for R&D staff and project management. Prior to joining the company, Lori was with Codexis, Inc., where she held a number of positions including Vice President of Systems Biology, Senior Directory of Technology and Innovation, and Manager of Market Development. Prior to Codexis she was head of the Core Technology Group at Maxgyen, Inc.
Dr. Giver has focused her career on the directed evolution of nucleic acids, proteins and organisms. She has chaired several conferences in the field including Enzyme Engineering XXI and Applications for Enzyme Technologies 2013. She is an author on more than 10 scientific publications and over 50 patents and patent applications. She received a Bachelor of Science degree in Molecular and Cell Biology from the University of California-Berkeley and Ph.D in Molecular Cell and Developmental Biology from Indiana University, Bloomington. Dr. Giver did her post-doctoral research at the California Institute of Technology in the laboratory of Dr. Frances Arnold.
Arild Johannessen, Dr. Scient
Vice President, Fermentation
Arild Johannessen, Dr. Scient (Ph.D.), is Vice President, Fermentation at Calysta, with responsibility for fermentation R&D and project management. He was named to his current position in 2017, and from 2014 to 2017 served as Calysta’s Vice President, Nutrition. He joined the company in 2014 as a result of the acquisition of BioProtein AS. Previously, Dr. Johannessen was with the International Research Institute of Stavanger (Norway) (IRIS) where he held positions including Research Director for Biotechnology and Managing Director for the IRIS biotechnology subsidiary. Prior to IRIS he was head of R&D at Biosentrum AS, and a scientist at Norferm AS.
Dr. Johannessen has focused his career on large scale microbial fermentation. He has been an invited speaker at conferences in the field of microbial production, with a special emphasis on fermentation using gases. He is an author of approximately 10 scientific publications and more than 10 patents and patent applications. He received a Dr. Scient (Ph.D.) in 1996 from the University of Bergen, and did his post-doctoral research at University of Bergen in the laboratory of Dr. Ian Pryme.
Senior Director and FeedKind® Product Manager
Allan LeBlanc is Senior Director and FeedKind Product Manager. He was named to his current position in 2017, and previously served as Product Manager, FeedKind®. He is responsible for global market and sales strategy of Calysta nutritional products including prioritization by geography and species. He also provides market intelligence guiding future product development. Mr. LeBlanc joined Calysta in 2013 as Director of Corporate Development where he worked on fundraising, the acquisition of BioProtein A/S, and financial planning and analysis.
Prior to joining Calysta, Mr. LeBlanc worked in venture capital at Ballast Point Ventures, where he focused on the pharmaceutical and healthcare industry. He also has prior experience in investment banking at Raymond James, where he worked on both mergers and acquisitions and public equity offerings for airlines and environmental services companies. Mr. LeBlanc holds an MBA from the University of California-Berkeley’s Haas School of Business and a Bachelor of Science degree from the University of Florida.
Vice President, Business Development
Mr. Leong joined Calysta in 2015. He has responsibility for all business development strategy and program execution, including broadening the Calysta portfolio of strategic partnerships. He joined Calysta from Chemtex, an international technology and engineering organization, where he was the Executive Vice President responsible for worldwide marketing and business development. At Chemtex he played an integral role in building the renewable and sustainable products business, including launching and licensing Beta Renewables’ cellulosic ethanol technology.
Before joining Chemtex in 2008, Mr. Leong led the marketing and business development activities for the downstream petrochemical and chemical business of Aker Solutions, a global engineering and construction contractor. Over his 20 year tenure with the group, he was based in a number of international locations including Canada, Japan, Hong Kong, Singapore and the United Kingdom. He holds a bachelor of applied science degree in chemical engineering from the University of British Columbia and is a registered professional engineer in Canada.
Josh Silverman, Ph.D.
Chief Product and Innovation Officer
Josh Silverman, Ph.D. is Calysta’s Chief Product and Innovation Officer and Founder. He was appointed to his current position in 2016. Dr. Silverman served as Calysta’s Chief Technology Officer from 2014-2016, and prior to that served as Chief Scientific Officer. Dr. Silverman is an experienced biotechnology entrepreneur with a history of successful development of novel technology platforms. Prior to founding Calysta, Dr. Silverman held positions at two public biotechnology companies, Maxygen, Inc. and Amgen, Inc. as well as serving as VP of Product development for Amunix, Inc. He has been involved in the founding and financing of five startup biotechnology companies (Avidia, Versartis, Diartis, Siluria, and Calysta). His efforts contributed to raising over $110 million in equity financing across these companies, as well as the sale of Avidia for $290M three years after founding the company and an IPO by Versartis in 2014 which raised $126 million.
Dr. Silverman is generally interested in tools and applications of biological engineering as a robust and predictable engineering discipline. He serves as an advisor for a number of biotechnology companies and is a frequent speaker at scientific meetings. He has been directly involved in successfully bringing three novel biopharmaceuticals from early phase research into clinical trials, with experience in both regulatory filings and drug manufacturing. He is an author on more than 10 scientific publications as well as over 30 patents and pending patent applications. He received his B.Sc. in Molecular Biology from UC San Diego and Ph.D. in Biochemistry from Stanford University.
Chief Financial Officer and Chief Sustainability Officer
Lynsey Wenger joined Calysta in 2016 as Chief Financial Officer and Chief Sustainability Officer. She is responsible for the company’s financial strategy, planning and management, and for expansion and implementation of Calysta’s long term sustainability strategy and programs. Ms. Wenger joined Calysta following a 16-year career with The Goldman Sachs Group, where she spent the greater part of the last decade specializing in global natural resources investment banking. She will have responsibility for the company’s financial strategy, planning and management, and for expansion and implementation of Calysta’s long term sustainability strategy and programs.
During Ms. Wenger’s career at Goldman Sachs, she managed and led investment banking activities in global natural resources ranging from international mergers and acquisitions and IPOs to multimillion-dollar equity transactions and debt placements. Her industry experience includes natural gas and electric utilities, power, renewables and alternative energy. Most recently, Ms. Wenger served as a Vice President in the Investment Banking Division, with responsibility for transactions in the corporate power and utility sectors. Previously, she served in the Americas Financing Group as Head of Investment Grade Power, Utility and Midstream Debt Capital Markets. Earlier in her career she held positions in Equity Derivative Sales in the United States and Australia.
Ms. Wenger holds an MBA from The Wharton School at the University of Pennsylvania and a Bachelor of Arts degree from Duke University.
Kumiko Yoshinari, Ph.D., CFA
Director, Project Finance
Kumiko Yoshinari, Ph.D., CFA, joined Calysta as Director, Project Finance in 2016. She has responsibility for the company’s project development and finance.
Dr. Yoshinari served for nearly 25 years at the International Finance Corporation (IFC), a unit of the World Bank Group. At IFC, she structured more than 40 investment transactions valued at over $2 billion in Asia, Europe and Africa. She served as Principal Advisor, Sustainable Energy Finance, with responsibility for financing transactions in renewable energy and energy efficiency. She also held a variety of other positions including Principal Strategist, and Division Manager for East Asia. Just prior to joining Calysta, Dr. Yoshinari originated, developed and structured financings for solar power/energy storage and wind power projects jointly with her business partners.
Dr. Yoshinari holds a Bachelor’s degree in economics from the University of Washington, a Master’s degree in public policy from Harvard University and a Ph.D. in applied economics from the Universite de Paris (IX). She is also a Chartered Financial Analyst.